Most adults who want to lose weight safely and effectively are good candidates for our medical weight loss program
As well as reducing localised fat, the treatment can improve the appearance of skin elasticity and firmness in the treated area supporting a smoother, more contoured result overall
Importantly, 100 mg/kg cinchonine ameliorated hepatic steatosis and fibrosis in NASH mice
If your employer's plan excludes anti-obesity medications entirely (common in self-insured plans), your options are: the cash-pay manufacturer programs described above, asking your HR department whether the exclusion can be reconsidered (especially if your employer is large enough to modify the plan), or using the medication under a different indication (for example, Ozempic for type 2 diabetes, if applicable)
The chronic nature of these conditions presents real challenges for active individuals

Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p 3 pounds/week associated with higher risk
